Eli Lilly became the first drugmaker to reach a $1 trillion market valuation, a milestone the company attributed to blockbuster revenue from its obesity and metabolic medicines. The firm’s market cap surge reflects rapid adoption of GLP-1–class therapies and investor expectations for continued sales growth and label expansions. Lilly’s valuation now rivals major tech names and highlights a dramatic re-rating of biopharma tied to weight‑loss therapeutics. The milestone intensifies scrutiny on pricing, payer access and competitive dynamics as other large players and startups vie to capture portions of the obesity market.